(CRVL) CorVel - Overview
Stock: Workers Comp, Claims Management, Bill Review, Network Solutions, Case Management
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 37.7% |
| Relative Tail Risk | -9.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.24 |
| Alpha | -73.23 |
| Character TTM | |
|---|---|
| Beta | 0.608 |
| Beta Downside | 0.256 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.11% |
| CAGR/Max DD | -0.11 |
Description: CRVL CorVel January 09, 2026
CorVel Corp (NASDAQ:CRVL) delivers technology-enabled solutions for workers’ compensation, general and auto liability, and hospital-bill auditing, leveraging AI, machine learning, and natural language processing to lower health-care episode costs and improve care quality. Its service suite spans automated fee auditing, provider network management, retrospective utilization review, pharmacy and inpatient bill review, as well as broader patient-management functions such as 24/7 nurse triage, case management, vocational rehabilitation, and life-care planning for self-insured payors.
Key recent metrics (FY 2023): revenue of roughly $1.2 billion, up about 13 % year-over-year, and an adjusted EBITDA margin near 12 %, reflecting the scalability of its AI-driven audit platform, which industry studies estimate can cut claim-processing costs by 10-15 %. The U.S. workers-compensation market is projected to expand at a 4 % CAGR through 2028, driven by rising labor costs, tighter regulatory scrutiny, and increasing adoption of digital claim-management tools-trends that directly benefit CorVel’s addressable universe.
For a deeper dive into CRVL’s valuation metrics, the ValueRay platform offers a concise, data-driven overview.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 105.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -4.60 > 1.0 |
| NWC/Revenue: 22.67% < 20% (prev 19.10%; Δ 3.57% < -1%) |
| CFO/TA 0.16 > 3% & CFO 103.0m > Net Income 105.7m |
| Net Debt (-192.8m) to EBITDA (167.6m): -1.15 < 3 |
| Current Ratio: 1.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.6m) vs 12m ago -0.88% < -2% |
| Gross Margin: 24.20% > 18% (prev 0.22%; Δ 2397 % > 0.5%) |
| Asset Turnover: 159.1% > 50% (prev 161.7%; Δ -2.62% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 10.00
| A: 0.33 (Total Current Assets 463.9m - Total Current Liabilities 250.4m) / Total Assets 644.8m |
| B: 1.52 (Retained Earnings 982.4m / Total Assets 644.8m) |
| C: 0.23 (EBIT TTM 136.7m / Avg Total Assets 591.8m) |
| D: 4.62 (Book Value of Equity 1.24b / Total Liabilities 269.1m) |
| Altman-Z'' Score: 13.54 = AAA |
Beneish M -3.16
| DSRI: 0.89 (Receivables 102.1m/106.2m, Revenue 941.5m/871.3m) |
| GMI: 0.93 (GM 24.20% / 22.40%) |
| AQI: 0.93 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.08 (Revenue 941.5m / 871.3m) |
| TATA: 0.00 (NI 105.7m - CFO 103.0m) / TA 644.8m) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of CRVL shares?
Over the past week, the price has changed by -30.10%, over one month by -29.95%, over three months by -35.42% and over the past year by -60.35%.
Is CRVL a buy, sell or hold?
What are the forecasts/targets for the CRVL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 35.9 | -26.2% |
CRVL Fundamental Data Overview February 05, 2026
P/S = 2.8342
P/B = 9.8686
Revenue TTM = 941.5m USD
EBIT TTM = 136.7m USD
EBITDA TTM = 167.6m USD
Long Term Debt = 28.1m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 8.13m USD (from shortTermDebt, last fiscal year)
Debt = 37.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -192.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.45b USD (2.65b + Debt 37.2m - CCE 230.0m)
Interest Coverage Ratio = unknown (Ebit TTM 136.7m / Interest Expense TTM 0.0)
EV/FCF = 35.52x (Enterprise Value 2.45b / FCF TTM 69.1m)
FCF Yield = 2.82% (FCF TTM 69.1m / Enterprise Value 2.45b)
FCF Margin = 7.34% (FCF TTM 69.1m / Revenue TTM 941.5m)
Net Margin = 11.23% (Net Income TTM 105.7m / Revenue TTM 941.5m)
Gross Margin = 24.20% ((Revenue TTM 941.5m - Cost of Revenue TTM 713.7m) / Revenue TTM)
Gross Margin QoQ = 23.31% (prev 24.28%)
Tobins Q-Ratio = 3.81 (Enterprise Value 2.45b / Total Assets 644.8m)
Interest Expense / Debt = 50.67% (Interest Expense 18.9m / Debt 37.2m)
Taxrate = 25.0% (8.06m / 32.2m)
NOPAT = 102.6m (EBIT 136.7m * (1 - 25.00%))
Current Ratio = 1.85 (Total Current Assets 463.9m / Total Current Liabilities 250.4m)
Debt / Equity = 0.10 (Debt 37.2m / totalStockholderEquity, last quarter 375.7m)
Debt / EBITDA = -1.15 (Net Debt -192.8m / EBITDA 167.6m)
Debt / FCF = -2.79 (Net Debt -192.8m / FCF TTM 69.1m)
Total Stockholder Equity = 350.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.87% (Net Income 105.7m / Total Assets 644.8m)
RoE = 30.14% (Net Income TTM 105.7m / Total Stockholder Equity 350.8m)
RoCE = 36.09% (EBIT 136.7m / Capital Employed (Equity 350.8m + L.T.Debt 28.1m))
RoIC = 29.95% (NOPAT 102.6m / Invested Capital 342.4m)
WACC = 8.05% (E(2.65b)/V(2.68b) * Re(8.16%) + (debt cost/tax rate unavailable))
Discount Rate = 8.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 81.11% ; FCFF base≈74.4m ; Y1≈91.8m ; Y5≈156.4m
Fair Price DCF = 54.85 (EV 2.62b - Net Debt -192.8m = Equity 2.81b / Shares 51.2m; r=8.05% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -64.23 | EPS CAGR: -20.15% | SUE: N/A | # QB: 0
Revenue Correlation: 98.92 | Revenue CAGR: 8.86% | SUE: N/A | # QB: 0